Skip to main content

Table 9 Base degradation peak results

From: Development and validation of stability indicating UPLC method for the simultaneous estimation of triamterene and hydrochlorothiazide in combined dosage forms using quality by design approach

 

Sample

Retention time

Area

Height

USP tailing

USP plate

Purity angle

Purity threshold

01

 

0.067

      

02

Peak1

0.921

998,471

396,915

 

292.97

  

03

Triamterene

0.981

810,006

307,869

 

1445.16

12.801

3.904

04

Peak3

1.285

      

05

 

1.393

9952

3440

1.26

4686.18

2.959

3.398

06

Peak4

1.549

14,828

4598

1.12

4742.60

1.990

2.620

07

HCTZ

1.744

937,058

238,214

1.34

4367.71

0.391

0.286

08

 

2.083

125

208

1.11

71,046.96

  

09

 

2.225

90

180

1.00

216,122.28

  

10

Peak6

2.516

      

11

 

2.760

202

255

1.21

119,996.94

  

12

 

2.809

152

282

1.00

222,599.98

  

13

 

3.507

459

426

0.60

106,744.19

  

14

Peak7

4.134

      

15

 

4.533

113

226

1.00

939,602.49

  

16

 

5.010

177

249

1.30

421,643.03

  

17

Peak8

5.709

99

181

1.09

877,705.41